Streptokinase

Comprehensive Clinical Guide: Streptokinase (Fibrinolytic Agent)

1. Introduction and Overview

Streptokinase is a potent, non-enzymatic protein produced by group C beta-hemolytic streptococci. In the clinical landscape, it serves as a cornerstone thrombolytic (fibrinolytic) medication. Unlike modern tissue plasminogen activators (tPA) that are clot-specific, Streptokinase acts systemically to dissolve blood clots by activating the body’s endogenous fibrinolytic system.

Historically, Streptokinase transformed the management of acute myocardial infarction (AMI). While its usage has evolved with the advent of primary percutaneous coronary intervention (PCI), it remains a vital therapeutic option in resource-limited settings and for specific thromboembolic conditions where more expensive, clot-specific agents are unavailable or contraindicated.

2. Mechanism of Action: The Biochemical Cascade

Streptokinase does not possess intrinsic enzymatic activity. Instead, it functions as a catalytic activator of the fibrinolytic system.

The Activation Pathway

1. Complex Formation: Upon administration, Streptokinase forms a 1:1 stoichiometric complex with circulating plasminogen.
2. Conformational Change: This binding induces a conformational change in the plasminogen molecule, exposing its active site.
3. Enzymatic Conversion: This complex then acts as an activator, converting other uncomplexed plasminogen molecules into the active enzyme plasmin.
4. Fibrinolysis: Plasmin is a non-specific protease that degrades fibrin clots, fibrinogen, and other plasma proteins (Factors V, VIII, and prothrombin), effectively dissolving the thrombus.

Key Pharmacodynamic Feature: The Systemic State

Because Streptokinase consumes circulating plasminogen and fibrinogen throughout the entire vascular system (not just at the site of the clot), it induces a "lytic state." This systemic effect is the primary reason for the increased bleeding risk associated with Streptokinase compared to newer fibrin-specific agents like Alteplase.

3. Pharmacokinetics

Understanding the kinetic profile of Streptokinase is essential for managing its short half-life and its immunogenic nature.

Note: Because Streptokinase is derived from streptococcal bacteria, most patients have pre-existing antibodies. This necessitates a loading dose to neutralize circulating antibodies before therapeutic thrombolysis can occur.

4. Clinical Indications & Usage

Streptokinase is indicated for conditions where rapid thrombolysis is necessary to restore perfusion.

Primary Indications

• Acute Myocardial Infarction (AMI): Used to lyse coronary artery thrombi to restore myocardial perfusion, ideally within 6–12 hours of symptom onset.
• Deep Vein Thrombosis (DVT): Used for extensive proximal DVT to reduce the risk of post-thrombotic syndrome.
• Pulmonary Embolism (PE): Indicated for massive PE associated with hemodynamic instability.
• Arterial Thrombosis/Embolism: Used for peripheral arterial occlusions.
• Occluded Cannulae/Shunts: Used in low doses to clear clots from hemodialysis catheters.

Dosage Guidelines (General)

• AMI: 1.5 million IU administered intravenously over 60 minutes.
• DVT/PE: Loading dose of 250,000 IU over 30 minutes, followed by 100,000 IU/hour for 24–72 hours.
• Cannula Clearance: 10,000–25,000 IU in 2 mL of saline, instilled into the catheter and aspirated after 2 hours.

5. Contraindications and Risks

Absolute Contraindications

The risk of catastrophic hemorrhage outweighs any potential benefit in the following scenarios:
* Any prior intracranial hemorrhage.
* Known structural cerebral vascular lesion (e.g., AVM).
* Known malignant intracranial neoplasm.
* Ischemic stroke within the last 3 months.
* Suspected aortic dissection.
* Active internal bleeding or bleeding diathesis.
* Significant closed-head or facial trauma within 3 months.

Relative Contraindications

• Uncontrolled severe hypertension (BP >180/110 mmHg).
• Recent major surgery (within 3 weeks).
• Current use of anticoagulants (e.g., Warfarin).
• Pregnancy.
• Active peptic ulcer disease.

Adverse Effects

1. Hemorrhage: The most severe risk (intracranial, gastrointestinal, or retroperitoneal).
2. Hypersensitivity: Urticaria, bronchospasm, and anaphylaxis (due to its protein nature).
3. Hypotension: Often transient during rapid infusion.
4. Reperfusion Arrhythmias: Common during AMI treatment as the clot dissolves and tissue is re-perfused.

6. Drug Interactions

• Anticoagulants (Heparin, Warfarin, DOACs): Concurrent use significantly increases the risk of life-threatening hemorrhage.
• Antiplatelet Agents (Aspirin, Clopidogrel): Increases the risk of bleeding; however, aspirin is often used concurrently in AMI protocols under strict monitoring.
• NSAIDs: Potentiate the bleeding risk by inhibiting platelet function.

7. Pregnancy and Lactation

• Pregnancy: Streptokinase is classified as Category C. It should only be used if the potential benefit justifies the potential risk to the fetus. It does not cross the placenta, but it may cause premature placental separation or uterine hemorrhage.
• Lactation: It is unknown if Streptokinase is excreted in human milk. Discontinue breastfeeding during treatment or use with extreme caution.

8. Overdose Management

In the event of an overdose or life-threatening hemorrhage:
1. Stop the infusion immediately.
2. Replace coagulation factors: Administer Fresh Frozen Plasma (FFP), cryoprecipitate, or platelets as indicated by coagulation studies.
3. Antifibrinolytic Agents: Consider the administration of Aminocaproic acid or Tranexamic acid to inhibit the fibrinolytic cascade.
4. Supportive Care: Hemodynamic stabilization and blood transfusions as needed.

9. Frequently Asked Questions (FAQ)

1. Why do we rarely use Streptokinase in the US anymore?

Modern clinical practice in developed nations favors fibrin-specific agents like Alteplase (tPA) or Tenecteplase. These are less immunogenic and carry a lower risk of systemic bleeding.

2. Can I repeat a dose of Streptokinase?

Generally, no. Because Streptokinase is highly immunogenic, the body develops high titers of anti-streptokinase antibodies after the first dose. These antibodies can persist for months or years, rendering subsequent doses ineffective and increasing the risk of anaphylaxis.

3. What is the difference between Streptokinase and tPA?

tPA is "clot-specific," meaning it activates plasminogen primarily at the site of the fibrin clot. Streptokinase is "systemic," meaning it activates plasminogen throughout the entire bloodstream, which increases the risk of bleeding elsewhere in the body.

4. What monitoring is required during infusion?

Clinicians must monitor vital signs every 15 minutes, perform a baseline and serial neurological exam (to detect intracranial hemorrhage), and check coagulation parameters (PT, aPTT, fibrinogen levels).

5. Why does hypotension occur during administration?

Hypotension is often a reaction to the rapid release of bradykinin or a hypersensitivity reaction to the streptococcal protein. Slowing the infusion rate usually resolves this.

6. Is Streptokinase effective for strokes?

No. Streptokinase is contraindicated in ischemic stroke because it significantly increases the risk of intracranial hemorrhage, which is far higher than the benefit provided in stroke patients.

7. How do I clear a blocked dialysis catheter?

A low-dose "dwell" technique is used. A small volume (usually 10,000–25,000 IU) is injected into the catheter, left for 1–2 hours, and then aspirated. This minimizes systemic exposure.

8. What is a "Lytic State"?

A lytic state occurs when the systemic levels of plasmin are so high that fibrinogen and other clotting factors are depleted. This makes the patient unable to clot effectively, leading to high bleeding risk.

9. Can Streptokinase be used in patients with a history of Strep throat?

Yes, most people have some level of antibodies due to prior exposure to streptococcal bacteria. The standard loading dose is specifically designed to neutralize these circulating antibodies before the thrombolytic effect begins.

10. What is the most common cause of death after Streptokinase administration?

The most common life-threatening complication is intracranial hemorrhage. Strict adherence to contraindication checklists is the best way to prevent this.

10. Clinical Summary for Healthcare Providers

Streptokinase remains a potent tool in the clinical arsenal. When utilized, success depends on patient selection, strict adherence to infusion protocols, and constant vigilance for signs of hemorrhage. While newer agents have superseded it in high-resource hospitals, its ability to save lives in the context of AMI and massive PE makes it an essential medication for the global medical community.

Disclaimer: This document is for educational purposes for healthcare professionals. Always consult your institution's latest formulary guidelines and the most current manufacturer-provided package insert before administering any thrombolytic medication.